What Altnoids are Available in Japan? A Handy Guide & FAQ

Japan’s cannabinoid scene moves faster than you can say “CBD latte.” One month, a new acronym is everywhere; the next, it has vanished from shop menus, group chats, and the collective memory of anyone who does not enjoy regulatory paperwork.

This guide tracks cannabinoids and altnoids available in Japan, including familiar names such as CBD and CBG alongside newer compounds and proprietary blends. It is designed as a living field guide: a way to decode the labels, understand how products are commonly marketed, and spot which names belong in the “historical context” drawer.

A quick vocabulary check before we begin: cannabinoids are the broad umbrella, including CBD, CBG, THC, and many others. Altnoids is informal shorthand for newer or alternative cannabinoid products, often made by chemically converting hemp-derived starting materials. Not every cannabinoid is an altnoid, and not every altnoid is the same kind of thing.

👉 Below you’ll find a set of charts showing current altnoids available in Japan. Just keep in mind that the rules can change at any time. Explore with curiosity but proceed with caution. And if there’s something I’m missing, please let me know: maryjaneinjapan@gmail.com

⚠️ Important: This page is for general information, not legal or medical advice. Japan’s rules can change quickly. Product availability, formulations, and compliance can also change faster than I can update.

Regulatory update: CBN became a designated drug in Japan on June 1, 2026. It is included below for historical context only, not as a currently available consumer option.

How to Read This Guide

Each entry explains what the ingredient is generally described as, where it comes from, and how brands or users commonly talk about its effects. Those effect descriptions are not guarantees. Dose, formula, terpenes, tolerance, setting, food, mood, hormones, health, and whether Mercury is in retrograde can all change the experience.

For the bigger picture—including the difference between natural, semi-synthetic, and fully synthetic cannabinoids—read: What Are Altnoids?

Non-Intoxicating or Mildly Felt Cannabinoids

These cannabinoids are generally discussed as non-intoxicating, lighter, or more wellness-oriented than stronger-effect altnoids. That does not mean every product will feel identical, especially when brands start mixing several ingredients together.

CBD (Cannabidiol)

Status: Current market listing
What it is: A major naturally occurring cannabinoid found in hemp.
Origin: Hemp-derived.
Commonly marketed for: Everyday calm, wellness routines, and non-intoxicating products.
What to know: CBD is the familiar starting point for much of Japan’s cannabinoid market. It is generally not intoxicating in the way THC is, but quality and documentation can vary wildly from product to product.
Japan note: Look for current THC-compliance testing and clear product information, especially with vapes, oils, and imported products.

CBG (Cannabigerol)

Status: Current market listing
What it is: A naturally occurring cannabinoid often called the “mother cannabinoid,” because it is a precursor in the plant’s cannabinoid pathway.
Origin: Hemp-derived.
Commonly marketed for: Clear, daytime-friendly, focused-calm vibes.
What to know: CBG is often blended with CBD rather than sold on its own. It is commonly positioned as a lighter, more alert counterpart to CBD—although the whole formula matters more than the name.

CBN (Cannabinol)*

Status: *Historical context — regulated in Japan from June 1, 2026
What it is: A cannabinoid associated with the breakdown or oxidation of THC.
Origin: Naturally occurring in cannabis, often discussed in relation to aged THC.
Previously marketed for: Nighttime relaxation, sleep-oriented blends, and a heavier wind-down feel.
What to know: CBN was a major name in Japan’s cannabinoid market until its designation in 2026. It remains here because readers will still encounter it in older reviews, product pages, and screenshots from the Before Times.
Japan note: Do not treat older CBN listings as current consumer options.

CBNO

Status: Current market listing
What it is: A CBN-related modified cannabinoid ingredient used in some Japanese products.
Origin: Lab-modified / supplier-specific formulation.
Commonly marketed or reported as: A more pronounced relaxation or body-focused effect than standard CBD-style products.
What to know: “CBNO” is a market label, and the exact chemistry and formula can vary by supplier. Check the specific product’s ingredient information and COA rather than assuming every CBNO product is identical.

CRD

Status: Current market listing
What it is: CRD is generally used to describe a stabilized cannabinoid distillate designed to resist (and help products resist) crystallization.
Origin: Blend distillate; formulas can include different cannabinoids depending on the supplier.
Commonly marketed for: A balanced cannabinoid experience shaped by the specific blend.
What to know: CRD is generally used to describe a stabilized cannabinoid distillate blend rather than one single cannabinoid. The exact ingredients and ratios can differ by product, so check the label or COA to see what is actually in that particular cart.

H4CBD (Hydrogenated Cannabidiol)

Status: Current market listing
What it is: A hydrogenated CBD-derived cannabinoid.
Origin: Commonly described as semi-synthetic, made from hemp-derived CBD.
Commonly marketed for: A fuller, more noticeable cannabinoid experience than standard CBD.
What to know: H4CBD is a hydrogenated CBD-derived cannabinoid. In Japan, it has appeared in products such as vapes and cannabinoid blends.
Mary Jane’s translation: CBD’s slightly more dressed-up cousin—not an automatic ticket to a THC-style high.

Read more: What is H4CBD?

CBV

Status: Current / niche market listing
What it is: A varin-series cannabinoid with a three-carbon side chain, related to the broader CBDV/THCV family.
Origin: Trace naturally occurring hemp cannabinoid; may also appear through conversion pathways in commercial products.
Commonly marketed for: Clear-headed relaxation and lighter, focus-friendly daytime use.
What to know: CBV is still a niche name compared with CBD or CBG, so it is worth checking whether a product explains its exact cannabinoid profile rather than relying on the acronym alone.

Psychoactive or Stronger-Effect Altnoids

These are the ingredients and blends most often marketed as offering a more noticeable “high,” euphoric effect, or THC-adjacent experience. That does not mean every product is equally strong. It does mean the product page deserves more than a two-second glance.

CBX

Status: Current market listing / emerging ingredient
What it is: A newer converted cannabinoid material appearing in Japan as isolate and distillate. Sellers describe it as a C4-series material, made from hemp-derived cannabinoid starting materials through chemical conversion and purification.
Commonly marketed or reported as: Fast-onset, noticeable, clear and sativa-leaning, with a relatively quick, clean finish.
What to know: CBX is still very new, with limited public research and inconsistent disclosure of its exact composition. Do not assume every CBX-labelled product contains the same compounds or will feel the same.

Read more: What Is CBX?

THAH

Status: Current market listing
What it is: A newer cannabinoid ingredient that began appearing in Japan in 2026. It is unrelated to THA, despite the names being similar.
Origin: Reportedly a newer imported raw material or a blended raw material; nobody is saying for sure, and exact supplier details can vary by product.
Commonly marketed or reported as: Slow-building euphoric head effects, deep body relaxation, and couch-lock territory.
What to know: Brands have positioned THAH as a stronger option for experienced users, with effects that may build over 20–30 minutes.

Read more: What is THAH?

CPX and HHBD

Status: Current market listing
What it is: Newer CBD-derived cannabinoid ingredients often used in stronger-effect formulas.
Origin: Commonly described as lab-converted from hemp-derived starting materials; terminology can vary by seller.
Commonly marketed or reported as: Clearer, more daytime-friendly effects with a euphoric lift and a relaxed body feel.
What to know: CPX and HHBD are often presented as “functional” or “sativa-like” options, but the blend, percentage, and terpene profile can change the actual experience dramatically.

Read more: What is HHBD?

CRDH / H4CBM

Status: Current / market terminology varies
What it is: A hydrogenated cannabinoid blend sometimes compared in marketing language to THC-adjacent compounds.
Origin: Created through lab conversion from hemp-derived cannabinoids.
Commonly marketed or reported as: Euphoric, head-forward, “sativa-like,” with a relaxed body effect.
What to know: CRDH and H4CBM naming can be supplier-specific, so do not assume every product using one of these labels contains the same formula.

CRDP

Status: Current market listing
What it is: A psychoactive cannabinoid blend that became especially visible in Japan after first appearing in Thailand.
Origin: Developed in Thailand; commonly described as hemp-derived but chemically modified.
Commonly marketed or reported as: Uplifting, euphoric, moderate-to-strong effects, often with a heavier body component.
What to know: CRDP is frequently used in stronger vape formulas.

Read more: What is CRDP?

CRDB

Status: Current / market terminology varies
What it is: A CRD-style blend featuring four-carbon-chain compounds, developed as a clearer alternative to CRDP.
Origin: Lab-produced from hemp-derived cannabinoids; reportedly from the same manufacturer family as CRDP.
Commonly marketed or reported as: Fast onset, uplifting and focus-friendly at first, then a smoother hybrid-style calm.
What to know: It is a newer, supplier-led label, so check the exact product formula and COA rather than treating the name as a universal standard.

Read more: What is CRDB?

CBPM

Status: Current / proprietary blend
What it is: A proprietary blend associated with CBNO, CBDO, and other cannabinoid ingredients.
Origin: U.S.-developed, especially marketed for edible products through Delta Farms.
Commonly marketed or reported as: A slower onset with a longer-lasting euphoric and relaxing effect.
What to know: Because it is a blend rather than a single standard compound, the product’s full cannabinoid profile matters more than the name alone.

H4CBH

Status: Current market listing
What it is: A hydrogenated cannabinoid related to the HHC family, with its own modifications.
Origin: Lab-modified from hemp-derived starting materials.
Commonly marketed or reported as: Brighter, more social, head-forward, and one of the stronger altnoids on the market at the time of writing.
What to know: H4CBH has earned a reputation as one of the stronger-feeling newer ingredients in Japan. Experiences vary, and the percentage on a label is not the whole story.

Read more: What is H4CBH?

THXE

Status: Current / watch-list context
What it is: A synthetic or “exotic” cannabinoid ingredient sometimes marketed as a THCH-style analogue.
Origin: Commonly described as U.S.-developed.
Commonly marketed or reported as: THC-like euphoria, sensory enhancement, and appetite-related effects.
What to know: This is exactly the kind of newer label where you should look for unusually clear documentation before treating the product as a casual experiment.

CBXE

Status: Current / proprietary blend
What it is: A proprietary cannabinoid blend associated with Delta Farms.
Origin: U.S.-developed through proprietary processes using hemp-derived cannabinoids.
Commonly marketed or reported as: A balanced, smooth euphoric effect, sometimes layered with CRDH-style ingredients.
What to know: As with any proprietary blend, the individual product’s COA and ingredient list matter more than the brand shorthand.

10-OH-HHC

Status: Watch list / unclear current Japan status
What it is: A semi-synthetic HHC-related cannabinoid, often described as a hydroxylated form or metabolite-related derivative of HHC.
Origin: Associated with HHC processing or lab conversion.
Commonly marketed or reported as: A gentler, mellower HHC-style effect.
Japan note: I have not confirmed a current compliant Japanese product or official legal status. Treat older listings with caution and check current COAs, product documentation, and official guidance before assuming availability.

Previously Available and/or Now Regulated in Japan

These names are included because you may still see them in older reviews, archived product pages, or the occasional screenshot from someone’s 2024 group chat. They are not a current-use list.

CBN

Status: Designated drug in Japan from June 1, 2026
Previously marketed for: Nighttime relaxation and sleep-oriented blends
What changed: Japan’s Ministry of Health, Labour and Welfare added CBN to the designated-drug list, meaning ordinary manufacture, import, sale, possession, and use are prohibited.
Read more: Good News: Kush JP Reformulated Products for a Post-CBN Japan

HHC, HHCH, THCH and THCPO

Status: Previously sold, later regulated
What to know: These compounds are part of the earlier wave of high-effect cannabinoids that helped shape Japan’s current altnoid market. Their regulation is a reminder that “available now” is not the same thing as “available forever.”

THA

Status: No longer available following the June 2026 CBN-related regulatory change, based on product formulations/market withdrawal
What to know: THA was a blended raw material rather than one single cannabinoid, and it appeared in a number of products before the regulatory shift. If you see it mentioned in an older Mary Jane in Japan review, check the publication date before assuming the product is still relevant.

Quick Q&A: Altnoids in Japan

Q: Are CBD and newer altnoids legal in Japan?
A: Yes—products discussed on Mary Jane in Japan were legal and publicly available in Japan at the time of publication or update. Japan’s cannabinoid rules can change quickly, though, so a product or ingredient that was available last year may not necessarily still be on shelves today. That is why I date my articles and update them when major changes happen. When buying any cannabinoid product, I still recommend choosing transparent brands that clearly show what is in the formula and provide current testing information.

Q: What’s the difference between non‑psychoactive and psychoactive altnoids?
A: Non-intoxicating or mildly felt cannabinoids, such as CBD and CBG, are generally discussed as not producing a classic THC-style high. Stronger-effect altnoids are marketed as more euphoric, body-heavy, or perception-shifting. The line is not always perfectly neat, though: dose, blends, and individual sensitivity matter.

Q: Where do these cannabinoids come from?
A: Some are naturally occurring in hemp or cannabis. Others are made by chemically converting hemp-derived starting materials, and some are proprietary blends with supplier-specific names. The more mysterious the name, the more important it is to read the product documentation.

Q: Could Japan ban these at any moment?
A: Japan’s cannabinoid market can change quickly. A compound that is openly discussed today may be restricted later, as CBN’s 2026 designation showed. This is why I do my best to keep the article dated and update it as the market changes.

The Bottom Line

Japan’s altnoid market is fascinating, creative, occasionally bewildering, and never especially good at choosing names that are easy to pronounce after one coffee. Still, you do not need to memorize every acronym. You just need to know the broad difference between lighter cannabinoids and stronger-effect altnoids, read current product documentation, and check the date before assuming something is still part of the landscape.

If you have spotted a cannabinoid currently appearing in Japan that deserves a closer look, email me at maryjaneinjapan@gmail.com. I cannot promise I will add every mysterious letter-combo immediately, but I am always curious.

Last updated: July 3, 2026

A Quick Summer Update from Mary Jane in JapanAugust 3, 2026Mary Jane

My Top 5 Legal Cannabinoid Products in Japan for Summer 2026July 6, 2026Mary Jane

Review: KushJP BOLT CBX x HHBDJuly 30, 2026Mary Jane

Quick note: This post may contain affiliate links. If you purchase them, it helps support Mary Jane in Japan and keeps this site running.